The levels of circulating tumor DNA and inflammatory proteins depict the clinical response in a patient with metastatic undifferentiated pleomorphic sarcoma, a case report

Authors

  • Christoffer Vannas Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden https://orcid.org/0000-0002-1029-0393
  • Mandy Escobar Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden https://orcid.org/0000-0002-9095-1429
  • Margaréta Tanyasiová Department of Oncology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden
  • Mathilda Kindeberg Sederblad Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden
  • Julia Nyström Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
  • Tobias Österlund Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden https://orcid.org/0000-0002-7870-8645
  • David Wennergren Department of Orthopaedics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden https://orcid.org/0000-0001-9882-6414
  • Daniel Andersson Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden https://orcid.org/0000-0002-4564-6652
  • Martin Dalin Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Children's Cancer Centre, Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden; Sahlgrenska Center for Cancer Research, Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden https://orcid.org/0000-0002-7516-0004
  • Åsa Torinsson Naluai Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden; Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; Core Facilities, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden https://orcid.org/0000-0002-0504-6492
  • Henrik Fagman Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Clinical Pathology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden https://orcid.org/0000-0001-5853-6295
  • Anders Ståhlberg Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Science for Life Laboratory, Institute of Biomedicine, University of Gothenburg, Sweden https://orcid.org/0000-0003-4243-0191

DOI:

https://doi.org/10.2340/1651-226X.2025.44337

Keywords:

circulating tumor DNA, liquid biopsy, Sarcoma, proteomics, Malignant Fibrous Histiocytoma, multiomics, case report

Downloads

Download data is not yet available.

References

Fletcher CDM. Pathology and genetics of tumours of soft tissue and bone. World Health Organization Classification of Tumours; IARC Press, Lyon. 2002.

Robles-Tenorio AS-LG. Undifferentiated pleomorphic sarcoma. StatPearls; Treasure Island, Florida, USA. 2024.

Fletcher CD, Gustafson P, Rydholm A, Willén H, Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol. 2001;19(12):3045–50.

https://doi.org/10.1200/JCO.2001.19.12.3045 DOI: https://doi.org/10.1200/JCO.2001.19.12.3045

Belal A, Kandil A, Allam A, Khafaga Y, El-Husseiny G, El-Enbaby A, et al. Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am J Clin Oncol. 2002;25(1):16–22.

https://doi.org/10.1097/00000421-200202000-00003 DOI: https://doi.org/10.1097/00000421-200202000-00003

Engellau J, Bendahl P-O, Persson A, Domanski HA, Åkerman M, Gustafson P, et al. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol. 2005;36(9):994–1002.

https://doi.org/10.1016/j.humpath.2005.07.008 DOI: https://doi.org/10.1016/j.humpath.2005.07.008

Burgess MA, Bolejack V, Schuetze S, Tine BAV, Attia S, Riedel RF, et al. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): final results of SARC028 expansion cohorts. J Clin Oncol. 2019;37(15_Suppl):11015.

https://doi.org/10.1200/JCO.2019.37.15_suppl.11015 DOI: https://doi.org/10.1200/JCO.2019.37.15_suppl.11015

Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6(5):479–91.

https://doi.org/10.1158/2159-8290.CD-15-1483 DOI: https://doi.org/10.1158/2159-8290.CD-15-1483

Aiyer S, Kim TH, Collier K, Pollock R, Verschraegen C, Stover DG, et al. Unlocking the potential of ctDNA in sarcomas: a review of recent advances. Cancers (Basel). 2025;17(6):1040.

https://doi.org/10.3390/cancers17061040 DOI: https://doi.org/10.3390/cancers17061040

Namløs HM, Boye K, Meza-Zepeda LA. Cell-free DNA in blood as a noninvasive insight into the sarcoma genome. Mol Aspects Med. 2020;72:100827.

https://doi.org/10.1016/j.mam.2019.10.004 DOI: https://doi.org/10.1016/j.mam.2019.10.004

Micallef P, Santamaría ML, Escobar M, Andersson D, Österlund T, Mouhanna P, et al. Digital sequencing is improved by using structured unique molecular identifiers. Genome Biol. 2025;26(1):37.

https://doi.org/10.1186/s13059-025-03504-x DOI: https://doi.org/10.1186/s13059-025-03504-x

Vannas C, Escobar M, Österlund T, Andersson D, Mouhanna P, Soomägi A, et al. Treatment monitoring of a patient with synchronous metastatic angiosarcoma and breast cancer using ctDNA. Int J Mol Sci. 2024;25(7):4023.

https://doi.org/10.3390/ijms25074023 DOI: https://doi.org/10.3390/ijms25074023

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–501.

https://doi.org/10.1016/S1470-2045(17)30624-1 DOI: https://doi.org/10.1016/S1470-2045(17)30624-1

Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–62.

https://doi.org/10.1038/s41571-021-00473-5 DOI: https://doi.org/10.1038/s41571-021-00473-5

Presti D, Dall’Olio FG, Besse B, Ribeiro JM, Di Meglio A, Soldato D. Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: a systematic review. Crit Rev Oncol Hematol. 2022;177:103773.

https://doi.org/10.1016/j.critrevonc.2022.103773 DOI: https://doi.org/10.1016/j.critrevonc.2022.103773

Oh SY, Kim S, Keam B, Kim TM, Kim D-W, Heo DS. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci Rep. 2021;11(1):19712.

https://doi.org/10.1038/s41598-021-99311-y DOI: https://doi.org/10.1038/s41598-021-99311-y

Mahoney KM, Ross-Macdonald P, Yuan L, Song L, Veras E, Wind-Rotolo M, et al. Soluble PD-L1 as an early marker of progressive disease on nivolumab. J Immuno Ther Cancer. 2022;10(2):e003527.

https://doi.org/10.1136/jitc-2021-003527 DOI: https://doi.org/10.1136/jitc-2021-003527

Scirocchi F, Strigari L, Di Filippo A, Napoletano C, Pace A, Rahimi H, et al. Soluble PD-L1 as a prognostic factor for immunotherapy treatment in solid tumors: systematic review and meta-analysis. Int J Mol Sci. 2022;23(22):14496.

https://doi.org/10.3390/ijms232214496 DOI: https://doi.org/10.3390/ijms232214496

Downloads

Additional Files

Published

2025-09-11

How to Cite

Vannas, C., Escobar, M., Tanyasiová, M., Kindeberg Sederblad, M., Nyström, J., Österlund, T., … Ståhlberg, A. (2025). The levels of circulating tumor DNA and inflammatory proteins depict the clinical response in a patient with metastatic undifferentiated pleomorphic sarcoma, a case report. Acta Oncologica, 64, 1212–1216. https://doi.org/10.2340/1651-226X.2025.44337

Issue

Vol. 64 (2025): Acta Oncologica

Section

Letter

Categories

License

Copyright (c) 2025 Christoffer Vannas, Mandy Escobar, Margaréta Tanyasiová, Mathilda Kindeberg Sederblad, Julia Nyström, Tobias Österlund, David Wennergren, Daniel Andersson, Martin Dalin, Åsa Torinsson Naluai, Henrik Fagman, Anders Ståhlberg

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.